BIVI - BioVie Inc. Stock Price, Fair Value and News

$1.59+0.12 (+8.16%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BIVI Price Action

Last 7 days

9.7%

Last 30 days

-7.0%

Trailing 12 Months

-94.8%

BIVI RSI Chart

BIVI Valuation

Market Cap

12.0M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

13.42

Price/Free Cashflow

-0.65

BIVI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BIVI Fundamentals

BIVI Revenue

Revenue (TTM)

893.6K

Rev. Growth (Yr)

-10.97%

Rev. Growth (Qtr)

-21.34%

BIVI Earnings

Earnings (TTM)

-18.5M

Earnings Growth (Yr)

-22.53%

Earnings Growth (Qtr)

-45.81%

BIVI Profitability

Return on Equity

-74.14%

Return on Assets

-68.89%

Free Cashflow Yield

-154.05%

BIVI Investor Care

Shares Dilution (1Y)

324.37%

Diluted EPS (TTM)

-11.44

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	893.6K	0
2024	0	0	1.0M	1.2M
2023	152.8K	239.0K	659.7K	794.4K
2022	40.2K	44.1K	78.0K	149.6K
2021	0	22.0K	28.8K	35.6K
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About BioVie Inc.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

CEO	Mr. Cuong Viet Do M.B.A., MBA
WEBSITE	https://bioviepharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	18

BioVie Inc. Frequently Asked Questions

What is the ticker symbol for BioVie Inc.? What does BIVI stand for in stocks?

BIVI is the stock ticker symbol of BioVie Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioVie Inc. (BIVI)?

As of Wed Dec 03 2025, market cap of BioVie Inc. is 11.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIVI stock?

You can check BIVI's fair value in chart for subscribers.

Is BioVie Inc. a good stock to buy?

The fair value guage provides a quick view whether BIVI is over valued or under valued. Whether BioVie Inc. is cheap or expensive depends on the assumptions which impact BioVie Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIVI.

What is BioVie Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BIVI's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 13.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIVI PE ratio will change depending on the future growth rate expectations of investors.